Lightstone Ventures is a leading global venture capital firm.
Business Model:
Revenue: $14.6M
Employees: 51-200
Address: 485 Ramona St
City: Palo Alto
State: CA
Zip: 94301
Country: US
Lightstone Ventures was founded in 2012 by the General Partners and other key members of the life science teams of Advanced Technology Ventures (ATV) and Morgenthaler. The firm was formed to capture the upside of investing in breakthrough life science companies during a time of unique opportunity in the space.
Contact Phone:
+16503883676
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
10/2019 | Cyteir Therapeutics | Series B | 40.2M |
1/2017 | Allay Therapeutics | Series A | 7M |
7/2015 | Ra Pharmaceuticals | Series B | 58.5M |
5/2019 | Locanabio | Series A | 55M |
4/2014 | Earlens | Series B | 40M |
10/2017 | Claret Medical | Series C | 0 |
9/2020 | Willow | Series C | 0 |
3/2023 | Relievant Medsystems | Series G | 0 |
2/2016 | Cala Health | Series B | 0 |
4/2016 | FIRE1 | Series B | 7.5M |
3/2017 | ALX Oncology | Convertible Note | 25M |
10/2017 | Gemini Therapeutics | Series A | 42.5M |
9/2019 | Bold Penguin | Series B | 32M |
6/2018 | Relievant Medsystems | Series E | 58M |
3/2015 | Nimbus Apollo | Series B | 43M |
4/2021 | WayCool | Series C | 0 |
1/2021 | Ligature Therapeutics | Seed Round | 0 |
4/2020 | Cerevance | Series B | 65M |
3/2016 | Tizona Therapeutics | Series B | 43M |
3/2023 | Shoulder Innovations | Series D | 0 |
10/2016 | Carrick Therapeutics | Series A | 95M |
3/2018 | Cyteir Therapeutics | Series B | 29M |
1/2023 | Volta Medical | Series B | 0 |
6/2023 | Tagworks Pharmaceuticals | Series A | 65M |
6/2023 | Tagworks Pharmaceuticals | Series A | 0 |
12/2021 | Choiceform | Venture Round | 30M |
9/2017 | Disarm Therapeutics | Series A | 30M |
12/2020 | Locanabio | Series B | 0 |
5/2017 | Cerevance | Series A | 5M |
11/2013 | Astria Therapeutics | Series B | 32.4M |
2/2019 | Nuvaira | Equity | 79M |
1/2019 | Allay Therapeutics | Series B | 25M |
4/2016 | Gemini Therapeutics | Seed Round | 2M |
2/2021 | Gemini Therapeutics | Post-IPO Equity | 0 |
8/2021 | Vigil Neuroscience | Series B | 0 |
8/2014 | Claret Medical | Series B | 0 |
2/2020 | ALX Oncology | Series C | 105M |
9/2022 | Nimbus Therapeutics | Venture Round | 0 |
3/2023 | FIRE1 | Venture Round | 0 |
10/2018 | Earlens | Series D | 0 |
3/2015 | ALX Oncology | Series A | 36M |
12/2020 | Tallac Therapeutics | Series A | 62M |
11/2020 | Shoulder Innovations | Venture Round | 0 |
1/2014 | FIRE1 | Series A | - |
10/2015 | Elcelyx Therapeutics | Series E | 0 |
2/2023 | Cerevance | Series B | 0 |
12/2016 | Cerevance | Series A | 21.5M |
12/2019 | Willow | Series C | 20M |
10/2020 | Relievant Medsystems | Venture Round | 0 |
12/2020 | Atsena Therapeutics | Series A | 0 |
6/2017 | Earlens | Series C | 0 |
6/2018 | Nimbus Therapeutics | Series B | 65M |
11/2020 | Catamaran Bio | Series A | 0 |
5/2018 | Medisix Therapeutics | Series A | 20M |
2/2021 | Cyteir Therapeutics | Series C | 0 |
5/2019 | Cala Health | Series C | 0 |
6/2016 | Earlens | Series C | 0 |
9/2014 | Flex Pharma | Venture Round | 0 |
1/2022 | ProVerum Medical | Series A | 0 |
1/2018 | FIRE1 | Series C | 49.6M |
4/2021 | Alchemab Therapeutics | Series A | 82.7M |
12/2022 | Carrick Therapeutics | Series C | 0 |
3/2015 | Nimbus Therapeutics | Series B | 43M |
1/2022 | ProVerum Medical | Series A | 0 |
12/2021 | Choiceform | Venture Round | 0 |
8/2021 | Vigil Neuroscience | Series B | 0 |
4/2021 | Alchemab Therapeutics | Series A | 0 |
4/2021 | WayCool | Series C | 0 |
2/2021 | Cyteir Therapeutics | Series C | 0 |
2/2021 | Gemini Therapeutics | Post-IPO Equity | 0 |
1/2021 | Ligature Therapeutics | Seed Round | 0 |
12/2020 | Atsena Therapeutics | Series A | 0 |
12/2020 | Locanabio | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|